Regeneron Pharmaceuticals Future Growth

Future criteria checks 0/6

Regeneron Pharmaceuticals is forecasted to grow earnings and revenue by 2.6% and 4.3% per annum respectively. EPS and ROE are also expected to grow by 2.7% and 16.2% per year respectively. Analyst coverage for Regeneron Pharmaceuticals stock is good.

Key information

2.6%

Earnings growth rate

2.7%

EPS growth rate

Biotechs earnings growth	14.3%
Revenue growth rate	4.3%
Future return on equity	16.2%
Analyst coverage	Good
Last updated	23 Mar 2023

Recent future growth updates

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 39% Undervaluation?

Oct 28

Recent updates

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Stay On Top Of Its Debt

Jan 16

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 39% Undervaluation?

Oct 28

Regeneron, Bayer Eylea gets FDA priority review for eye disorder in infants

Oct 12

Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt

Oct 10

Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition

Sep 29

Regeneron: Fortune Seems To Favor This Bold, Innovative Pharma

Sep 14

Regeneron says pivotal trials for less frequent Eylea injections reached main goals

Sep 08

Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M

Aug 03

Is Now The Time To Put Regeneron Pharmaceuticals (NASDAQ:REGN) On Your Watchlist?

Jul 26

Regeneron Post COVID Bolus

Jul 16

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Jul 08

FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness

Jun 29

Regeneron Pharmaceuticals: Lack Of Appreciation For The Purchase Of Libtayo

Jun 21

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jun 05

Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus Forecasts

May 21

Here's Why We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Is Well Worth Watching

Apr 24

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

Apr 08

Earnings and Revenue Growth Forecasts

NasdaqGS:REGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	13,972	4,252	4,612	5,389	20
12/31/2024	13,444	4,106	4,252	5,197	21
12/31/2023	12,617	3,758	4,000	4,948	23
12/31/2019	6,558	2,116	2,000	2,430	N/A
9/30/2019	6,622	2,144	1,995	2,371	N/A
6/30/2019	6,542	2,069	1,906	2,267	N/A
3/31/2019	6,572	2,428	2,095	2,473	N/A
12/31/2018	5,146	2,444	1,812	2,195	N/A
9/30/2018	6,365	1,798	1,628	2,033	N/A
6/30/2018	6,203	1,591	1,636	1,995	N/A
3/31/2018	6,065	1,428	1,268	1,570	N/A
12/31/2017	5,872	1,199	1,035	1,307	N/A
9/30/2017	5,517	1,278	803	1,118	N/A
6/30/2017	5,236	1,155	980	1,354	N/A
3/31/2017	4,979	963	1,326	1,784	N/A
12/31/2016	4,860	896	974	1,486	N/A
9/30/2016	4,732	797	N/A	1,377	N/A
6/30/2016	4,649	743	N/A	1,619	N/A
3/31/2016	4,435	741	N/A	1,477	N/A

Regeneron Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 39% Undervaluation?

Price target increased to US$748

Recent updates

Now 20% undervalued after recent price drop

Chairman of the Board exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approved Eylea Injection

Senior VP exercised options and sold US$1.7m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Expands the Marketing Authorization for Dupixent® (Dupilumab) in the European Union

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Stay On Top Of Its Debt

Regeneron Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Independent Director exercised options and sold US$1.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Libtayo (cemiplimab) Receives Approval in Japan for Advanced or Recurrent Cervical Cancer

Regeneron Pharmaceuticals, Inc. Demonstrates High and Durable Complete Response Rate Among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial

Executive VP of Finance & CFO exercised options and sold US$1.1m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Pivotal Odronextamab (Cd20xcd3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Debut At ASH

Executive VP of Finance & CFO exercised options and sold US$944k worth of stock

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types

Evkeeza(R) (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

Insider exercised options and sold US$18m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Libtayo (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

Insider exercised options and sold US$12m worth of stock

Regeneron Pharmaceuticals, Inc Announces Dupixent® (Dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

Regeneron Pharmaceuticals, Inc. Announces Libtayo in Combination with Chemotherapy Approved by the FDA as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Regeneron Pharmaceuticals, Inc. Updates Results from Two Positive Pivotal Trials Investigating Novel Aflibercept 8 Mg with 12- and 16-Week Dosing Regimens

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP of Finance & CFO exercised options and sold US$742k worth of stock

Abcellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 39% Undervaluation?

Regeneron Receives Six Months of U.S. Pediatric Exclusivity for Eylea® (Aflibercept) Injection

Executive VP of Finance & CFO exercised options and sold US$541k worth of stock

Regeneron Pharmaceuticals, Inc. Announces Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepted for Priority Review the Supplemental Biologics License Application for EYLEA Injection

Regeneron, Bayer Eylea gets FDA priority review for eye disorder in infants

Regeneron Pharmaceuticals, Inc. and Sanofi Present Late-Breaking Positive Results from Phase 3 Trial Evaluating the Investigational Use of Dupixent (dupilumab) in Children Aged 1 to 11 Years with Active Eosinophilic Esophagitis

Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt

Regeneron Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Regeneron Elects Craig B. Thompson to Board of Directors and Technology Committee of the Regeneron Board

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Approval of Dupixent® (Dupilumab) by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition

Price target increased to US$748

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

Regeneron Pharmaceuticals, Inc. Announces Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

Regeneron: Fortune Seems To Favor This Bold, Innovative Pharma

Regeneron Pharmaceuticals, Inc. Announces Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma

Price target increased to US$733

Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors

Independent Director exercised options and sold US$1.3m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Present Detailed Positive Results from the Second of Two Phase 3 Trials (PRIME) Evaluating Dupixent

Investor sentiment improved over the past week

Regeneron says pivotal trials for less frequent Eylea injections reached main goals

Regeneron: There Are Challenges But Growth To Resume In 2023

Regeneron monoclonal antibody gets WHO recommendation for Ebola

Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst

Independent Director recently sold US$4.3m worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Announces Encouraging Initial Data from Phase 1/2 Trial of REGN5678

Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M

Is Now The Time To Put Regeneron Pharmaceuticals (NASDAQ:REGN) On Your Watchlist?

Regeneron Post COVID Bolus

Regeneron Pharmaceuticals, Inc. Announces Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis

Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?

Regeneron Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquisition of Worldwide Exclusive License Rights of Libtayo from Sanofi Biotechnology SAS.

Regeneron Pharmaceuticals, Inc. Announces the U.S. Food and Drug Administration Has Accepted for Review the Eylea®

FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Regeneron Pharmaceuticals: Lack Of Appreciation For The Purchase Of Libtayo

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 47% Below Their Intrinsic Value Estimate